Abstract library

75 results for "cytotoxic agents".
#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Kosmas Daskalakis
#42 Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas: a Single-Center Experience.
Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Timo Deutschbein
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
#741 Lanreotide Activity and Synergy in Combination with Targeted Agents in Gastrointestinal Neuroendocrine Tumors (GI-NET): Ex Vivo Analysis of Programmed Cell Death (EVA/PCD) in GI-NETs Isolated from Patients with Advanced Disease
Introduction: Somatostatin receptor ligation can affect vascular signals, induce apoptosis and provide objective responses in some GI-NET patients.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Nick Brown
#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#1040 TIM16 Inhibition Decreases Calcitonin Secretion and Enhances Sensitivity to Paclitaxel in a Human Medullary Thyroid Carcinoma Cells
Introduction: TIM 16 protein is part of the traslocase complex TIM 23 situated in the mitochondrial inner membrane, encoded by the Magmas gene, that is overexpressed in several tumors. Magmas silencing causes a greater sensitivity to apoptotic stimuli. We recently demonstrated that, in a human medullary thyroid carcinoma cell line (TT), compound 5, a TIM 16 inhibitor, was not cytotoxic but enhanced the proapoptotic effects of staurosporine
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Teresa Gagliano
#629 Targeting Chaperone Activity and Chaperone Expression in Human GEP-NET Cells Can Repress Their Proliferation and Sensitize Them to Chemotherapy
Introduction: New approaches for better treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are acutely needed. Inhibitors of chaperone activity of heat shock protein 90 (Hsp90) seem to be promising agents but they upregulate cytoprotective chaperones Hsp70 and Hsp27.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Anna Demidkina
#1504 Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs
Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba
Keywords: Lung NETs, lanreotide
#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?
Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Anne-Sophie Dussol
#2233 Potential Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumors
Introduction: Prolonged biochemical remission after treatment with steroidogenesis inhibitors has been described in patients with Cushing’s syndrome due to ectopic adrenocorticotropin hormone (ACTH) production. Some studies have suggested antiproliferative and apoptotic effect of ketoconazole in human cancer cells.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Aura Dulcinea Herrera-Martínez
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.